크리네틱스 파마슈티컬스(CRNX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $84.70 (+0.31%), 시가총액 $4.04B, 52주 범위 $26.85 ~ $56.43.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess AC
크리네틱스 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
크리네틱스 파마슈티컬스의 현재 주가는 $84.70 (+0.31%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
크리네틱스 파마슈티컬스의 시가총액은 약 $4.04B입니다.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-r